Despite the SUR2 gain-of-function mutation being a cause of cardiovascular abnormalities observed in patients with Cantu syndrome, our results showed that pharmacological activation of SUR2 should be considered for treating PAH. The gene discussed is ABCC9; the disease is hypertrichotic osteochondrodysplasia Cantu type.